# HepZero:Heparin Free Dialysis With Evodial

Study · id `cardio:ct-nct01318486` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01318486](<https://clinicaltrials.gov/study/NCT01318486>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01318486

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.

## Technical summary

Registry record NCT01318486. Randomized; no masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2013-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 265 participants (enrolled count; ClinicalTrials.gov record NCT01318486, source copy `cardio:ctgov-nct01318486-2025-03-14`, retrieved 2026-10-26)
- Start date: 2011-03 (registry gives no type) (ClinicalTrials.gov record NCT01318486, source copy `cardio:ctgov-nct01318486-2025-03-14`, retrieved 2026-10-26)
- Primary completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01318486, source copy `cardio:ctgov-nct01318486-2025-03-14`, retrieved 2026-10-26)
- Completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01318486, source copy `cardio:ctgov-nct01318486-2025-03-14`, retrieved 2026-10-26)
- Countries: Belgium; Canada; France; Netherlands; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT01318486, source copy `cardio:ctgov-nct01318486-2025-03-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01318486-2025-03-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: HepZero:Heparin Free Dialysis With Evodial
- Condition: Chronic Kidney Disease
- Condition: Patients Requiring Heparin Free Dialysis Treatments
- Intervention (Other): Heparin free dialysis technique
- Intervention (Device): Evodial
- Lead sponsor: Vantive Health LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Statistical Analysis : CIC CHU Brabois Nancy
- Collaborator class: UNKNOWN
- Collaborator: Gambro Lundia AB
- Collaborator class: INDUSTRY
- Collaborator: Baxter Healthcare Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Vantive Health LLC (`cardio:org-vantive-health-llc`)
- Registry lists this organization as a collaborator: Baxter Healthcare Corporation (`cardio:org-baxter-healthcare-corporation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis (`cardio:pubmed-25007166`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ebe941c3dca131fe605ab11b4a57c4097885cfeed22b0eb1ef89f9103075cf70
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
